A phase II study has demonstrated the median PFS of second-line Bev + CP in EGFR-mutant NSCLC patients was 6.6 months, which was shorter than that of first-line Bev + CP with 9.2 months reported in BEYOND trials [15, 18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.